Certara, Inc. (NASDAQ:CERT) Given Average Recommendation of “Hold” by Brokerages

Certara, Inc. (NASDAQ:CERT) has been given a consensus rating of “Hold” by the nine brokerages that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $17.79.

A number of equities analysts have commented on CERT shares. Robert W. Baird cut their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. UBS Group lowered their price objective on Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Barclays cut their target price on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. Finally, KeyCorp decreased their price target on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th.

Certara Trading Up 2.3 %

NASDAQ CERT opened at $10.70 on Friday. Certara has a one year low of $10.35 and a one year high of $19.87. The firm has a market cap of $1.72 billion, a PE ratio of -27.44, a P/E/G ratio of 5.17 and a beta of 1.49. The firm’s fifty day moving average is $12.82 and its two-hundred day moving average is $15.16. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. During the same period in the prior year, the company earned $0.10 earnings per share. The firm’s revenue was up 3.2% on a year-over-year basis. Analysts expect that Certara will post 0.27 earnings per share for the current year.

Insider Activity at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.39% of the stock is currently owned by company insiders.

Institutional Trading of Certara

Several institutional investors and hedge funds have recently modified their holdings of the business. Mubadala Investment Co PJSC purchased a new position in shares of Certara during the 4th quarter worth approximately $169,135,000. Wasatch Advisors LP increased its position in Certara by 23.4% during the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after buying an additional 932,598 shares in the last quarter. Geneva Capital Management LLC raised its holdings in shares of Certara by 15.1% in the first quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after acquiring an additional 579,349 shares during the last quarter. Clearbridge Investments LLC lifted its position in shares of Certara by 0.8% in the first quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after acquiring an additional 32,846 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after acquiring an additional 273,095 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.